Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
30112
Description
Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease; ODM derived from: https://clinicaltrials.gov/show/NCT01150201
Lien
https://clinicaltrials.gov/show/NCT01150201
Mots-clés
Versions (2)
- 11/05/2018 11/05/2018 -
- 11/05/2018 11/05/2018 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
11 mai 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Kidney Disease NCT01150201
Eligibility Kidney Disease NCT01150201
- StudyEvent: Eligibility
Similar models
Eligibility Kidney Disease NCT01150201
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Age
Item
male or female 18 - 80 years of age
boolean
C0001779 (UMLS CUI [1])
Chronic Kidney Disease Stage | Renal function GFR estimation by MDRD | Other Coding
Item
presence of nondiabetic ckd stages 3 to 4 as defined by estimated glomerular filtration rate (egfr by 4-variable mdrd equation) as follows:
boolean
C1561643 (UMLS CUI [1,1])
C2074731 (UMLS CUI [1,2])
C2170215 (UMLS CUI [2])
C3846158 (UMLS CUI [3])
C2074731 (UMLS CUI [1,2])
C2170215 (UMLS CUI [2])
C3846158 (UMLS CUI [3])
Chronic kidney disease stage | Decreased glomerular filtration rate Moderate
Item
stage 3: moderate decrease in gfr 30-59 ml/min/1.73 sq.m
boolean
C2074731 (UMLS CUI [1])
C0853068 (UMLS CUI [2,1])
C0205081 (UMLS CUI [2,2])
C0853068 (UMLS CUI [2,1])
C0205081 (UMLS CUI [2,2])
Chronic kidney disease stage | Decreased glomerular filtration rate Severe
Item
stage 4: severe decrease in gfr 15-29 ml/min/1.73 sq.m
boolean
C2074731 (UMLS CUI [1])
C0853068 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0853068 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
Chronic Kidney Diseases | Kidney damage | Glomerular Filtration Rate | Variation Percentage
Item
ckd is defined as either kidney damage or gfr <60 ml/min/1.73 m2 for > 3 months with variations of less than 30% in the 3 months before screening
boolean
C1561643 (UMLS CUI [1])
C1408258 (UMLS CUI [2])
C0017654 (UMLS CUI [3])
C0205419 (UMLS CUI [4,1])
C0439165 (UMLS CUI [4,2])
C1408258 (UMLS CUI [2])
C0017654 (UMLS CUI [3])
C0205419 (UMLS CUI [4,1])
C0439165 (UMLS CUI [4,2])
ID.6
Item
early-morning urinary protein-to-creatinine ratio of >500 mg/g or 57 mg/mmol on at least 2 occasions four weeks apart
boolean
Informed Consent
Item
patients who are willing to give written, informed consent
boolean
C0021430 (UMLS CUI [1])
Estimated Glomerular Filtration Rate
Item
egfr < 15 or > 60 ml/min/1.73m2
boolean
C3811844 (UMLS CUI [1])
Urine protein/creatinine ratio measurement
Item
early-morning urinary protein-to-creatinine ratio of >5000 mg/g or 570 mg/mmol, or urinary protein-to-creatinine ratio of <500 mg/g or 57 mg/mmol
boolean
C1096054 (UMLS CUI [1])
Serum potassium measurement
Item
serum k+ > 5.2 mmol/l
boolean
C0302353 (UMLS CUI [1])
Bilateral renal artery stenosis
Item
presence of bilateral renal artery stenosis
boolean
C0856760 (UMLS CUI [1])
Losartan allergy | Hypersensitivity Aliskiren
Item
known allergy to losartan or aliskiren
boolean
C0571952 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C1120110 (UMLS CUI [2,2])
C0020517 (UMLS CUI [2,1])
C1120110 (UMLS CUI [2,2])
Angiotensin II receptor antagonist | Angiotensin-Converting Enzyme Inhibitors | Combined Modality Therapy
Item
patients who are receiving angiotensin ii receptor blocker / angiotensin converting enzyme inhibitor combination within 12 weeks of randomization
boolean
C0521942 (UMLS CUI [1])
C0003015 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
C0003015 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Adrenal Cortex Hormones | Anti-Inflammatory Agents, Non-Steroidal | Immunosuppressive Agents
Item
concurrent treatment with corticosteroids, nonsteroidal antiinflammatory drugs, or immunosuppressive agent
boolean
C0001617 (UMLS CUI [1])
C0003211 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
C0003211 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
Connective Tissue Diseases | Urinary tract obstruction
Item
patients with connective tissue disease or obstructive uropathy
boolean
C0009782 (UMLS CUI [1])
C0178879 (UMLS CUI [2])
C0178879 (UMLS CUI [2])
Malignant Neoplasms | Life Expectancy Limited
Item
patients with concomitant malignancy or any such conditions that will severely limit life expectancy
boolean
C0006826 (UMLS CUI [1])
C0023671 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
C0023671 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
Pregnancy | Pregnancy, Planned
Item
female who are pregnant or intending to conceive
boolean
C0032961 (UMLS CUI [1])
C0032992 (UMLS CUI [2])
C0032992 (UMLS CUI [2])
Childbearing Potential Contraceptive methods Unwilling
Item
female of child-bearing age who are unwilling to practice effective contraception
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
Informed Consent Unable
Item
patients who are unable to give informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,2])
Study Subject Participation Status
Item
patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study
boolean
C2348568 (UMLS CUI [1])